XT
NMTR

XTX Topco’s 9 Meters Biopharma NMTR Stock Holding History

XTX Topco’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,357
Closed -$27K – 1031
2021
Q4 		$27K Buy
1,357
+846
+166% +$18.9K 0.02% 610
2021
Q3 		$13K Sell
511
-510
-50% -$12K ﹤0.01% 647
2021
Q2 		$22K Buy
1,021
+483
+90% +$11.9K 0.01% 764
2021
Q1 		$13K Buy
+538
New +$16.5K 0.01% 659

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

XTX Topco's NMTR Position: Q1 2022 in Review

XTX Topco sold out of 9 Meters Biopharma (NMTR) in Q1 2022, closing a stake of 1,357 shares — an estimated $27K sold.

XTX Topco first reported a position in NMTR in Q1 2021 and held it in 4 quarters. The position peaked at $27K in Q4 2021. 101 funds tracked by Wall St. Rank hold NMTR as of Q1 2022.

  • XTX Topco reported no remaining 9 Meters Biopharma position as of Q1 2022 after selling out during the quarter.
  • XTX Topco sold 1,357 9 Meters Biopharma shares in Q1 2022, an estimated $27K.
  • XTX Topco first reported a position in 9 Meters Biopharma in Q1 2021 and held it in 4 quarters.
  • XTX Topco's 9 Meters Biopharma position peaked at $27K in Q4 2021.
  • 101 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q1 2022.

Based on XTX Topco's 13F filing for Q1 2022, filed 13 May 2022.